CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun 4, 2021–
Ribon Therapeutics, a medical stage biotechnology firm growing therapeutics concentrating on stress assist pathways, introduced constructive interim medical knowledge from the dose escalation portion of its first-in-human Part 1 trial evaluating RBN-2397, a small molecule inhibitor of PARP7, as a monotherapy in sufferers with superior stable tumors. Presenting the info in an oral presentation on the American Society of Medical Oncology (ASCO) Annual Assembly on June 4, 2021, can be Gerald S. Falchook, M.D., Director, Drug Growth, Sarah Cannon Analysis Institute at HealthONE, Denver, CO and Medical Investigator within the RBN-2397 Part 1 trial.
“We’re happy to see demonstration of goal inhibition and preliminary indicators of antitumor exercise on this early stage of medical growth of a novel goal,” mentioned Dr. Falchook. “Within the growth a part of the research, we are going to search to show definitive medical exercise in tumor sorts predicted to answer RBN-2397.”
The first aims of the research are to find out any dose limiting toxicities (DLTs), most tolerated dose (MTD), and set up the really helpful part 2 dose (RP2D). The dose escalation portion evaluated two dosing schedules with a number of ascending dose cohorts of RBN-2397. As of April 1, 2021, the dose escalation portion of the research, by which 50 sufferers had been enrolled, is full and the important thing outcomes are as follows:
- Single-agent RBN-2397 was well-tolerated at exposures predicted to be efficacious in preclinical research
- RP2D was 200 mg BID on a steady dosing schedule
- On this closely pretreated, heterogenous affected person inhabitants, preliminary antitumor exercise was noticed with one partial response (PR) in a affected person with HR+ breast most cancers and 9 sufferers with steady illness (SD) > 4 months
- Consists of one affected person with squamous cell carcinoma of lung (SCCL) who has been on research with SD for 17+ months and 29% tumor shrinkage submit knowledge cutoff date and a second SCCL affected person with SD for 4+ months and 19% tumor shrinkage
- Proof of mechanism demonstrated by improve in tumoral Sort I interferon (IFN) response and immune cells after remedy with RBN-2397
- Growth part is presently enrolling sufferers in numerous outlined cohorts, together with SCCL
“These outcomes validate our method to drug growth by concentrating on mobile stress and modulating the immune system to induce antitumor exercise,” mentioned Sudha Parasuraman, M.D., Chief Medical Officer, Ribon Therapeutics. “We count on the growth a part of the research to ascertain proof of idea for RBN-2397 monotherapy and sit up for increasing our growth program with the initiation of a Part 1b/2 mixture research with pembrolizumab in SCCL within the second half of 2021.”
On the conclusion of the ASCO Annual Assembly, a replica of the presentation can be accessible on the Ribon Therapeutics web site at https://ribontx.com/publications/.
RBN-2397 is an orally accessible small molecule inhibitor of PARP7 that Ribon Therapeutics is growing for the remedy of stable tumors. PARP7 is upregulated in response to mobile stress, together with genomic instability in cancers, and acts as a brake on the mobile stress response by negatively regulating the Sort I interferon response. By inhibiting PARP7 in tumor cells, RBN-2397 has been proven to immediately inhibit mobile proliferation and restore interferon signaling to stimulate an innate and adaptive antitumor immune response. RBN-2397 is presently in a Part 1 medical trial as a monotherapy in sufferers with superior stable tumors ( NCT04053673 ). PARP7 is overexpressed in numerous tumors, together with squamous cell carcinoma of the lung, or SCCL, which represents roughly 30% of all non-small cell lung cancers.
About Ribon Therapeutics
Ribon Therapeutics is a medical stage biotechnology firm growing therapeutics concentrating on novel enzyme households activated beneath mobile stress situations that contribute to illness. We’re exploring novel areas of biology to develop efficient remedies for sufferers with restricted therapeutic choices. Leveraging our proprietary BEACON + (Blocking the Enzyme Exercise Part of NAD + ) platform, we’re constructing a pipeline of selective, small molecule inhibitors to quite a few NAD + -utilizing enzymes, starting with monoPARPs, which have functions throughout a number of therapeutic areas. Our lead program is RBN-2397, a PARP7 inhibitor in medical growth for the remedy of most cancers. Ribon is positioned in Cambridge, Massachusetts. For extra data go to www.RibonTx.com.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20210604005047/en/
CONTACT: Brendan Burns
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY
SOURCE: Ribon Therapeutics
Copyright Enterprise Wire 2021.
PUB: 06/04/2021 07:00 AM/DISC: 06/04/2021 07:02 AM
Copyright Enterprise Wire 2021.